In this expert-led series, Professor Mario Castro explores insights from the VESTIGE clinical trial, examining the impact of targeting type 2 inflammation with DUPIXENT® (dupilumab) on outcomes that reflect changes in the underlying disease pathology, including mucus plugging and airway remodelling, and what this could mean for future treatment strategies in asthma.